Vera Therapeutics, Inc. (NASDAQ:VERA) Director Sells $3,580,597.80 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Maha Katabi sold 81,009 shares of the company’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $44.20, for a total value of $3,580,597.80. Following the transaction, the director now directly owns 3,547,437 shares in the company, valued at approximately $156,796,715.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Maha Katabi also recently made the following trade(s):

• On Monday, March 25th, Maha Katabi sold 340,000 shares of Vera Therapeutics stock. The stock was sold at an average price of $40.50, for a total value of $13,770,000.00.
• On Tuesday, January 30th, Maha Katabi bought 161,290 shares of Vera Therapeutics stock. The stock was purchased at an average cost of $31.00 per share, for a total transaction of $4,999,990.00.

Vera Therapeutics Stock Performance

Shares of NASDAQ VERA opened at $43.83 on Thursday. The company has a current ratio of 6.97, a quick ratio of 6.97 and a debt-to-equity ratio of 0.20. Vera Therapeutics, Inc. has a 12 month low of $5.95 and a 12 month high of $50.78. The stock has a 50 day moving average of $39.76 and a 200-day moving average of $22.93. The company has a market capitalization of $2.30 billion, a P/E ratio of -19.14 and a beta of 1.10.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on VERA. Raymond James raised Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $29.00 to $37.00 in a research report on Friday, January 26th. Oppenheimer initiated coverage on Vera Therapeutics in a research note on Thursday, January 25th. They issued an “outperform” rating and a $26.00 price target for the company. Wedbush raised their price target on Vera Therapeutics from $21.00 to $34.00 and gave the company a “neutral” rating in a research note on Thursday, March 21st. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Vera Therapeutics in a research note on Wednesday, December 27th. Finally, Cantor Fitzgerald initiated coverage on Vera Therapeutics in a research note on Monday, January 8th. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Vera Therapeutics currently has a consensus rating of “Buy” and an average target price of $32.29.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY boosted its stake in Vera Therapeutics by 42.2% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 1,888 shares of the company’s stock valued at $30,000 after purchasing an additional 560 shares during the period. Tower Research Capital LLC TRC boosted its stake in Vera Therapeutics by 810.4% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,834 shares of the company’s stock valued at $38,000 after purchasing an additional 4,303 shares during the period. Ameritas Investment Partners Inc. boosted its stake in Vera Therapeutics by 163.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,792 shares of the company’s stock valued at $45,000 after purchasing an additional 1,731 shares during the period. UBS Group AG bought a new stake in Vera Therapeutics in the 1st quarter valued at $47,000. Finally, Royal Bank of Canada boosted its stake in Vera Therapeutics by 94.8% in the 2nd quarter. Royal Bank of Canada now owns 3,339 shares of the company’s stock valued at $54,000 after purchasing an additional 1,625 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis.